Výsledky vyhledávání - "Peter F A, Mulders"

Akademický článek

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Autor: Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp

Publikováno v: Pharmaceuticals, Vol 15, Iss 5, p 570 (2022)

In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice. BAL

Externí odkaz: https://doaj.org/article/d9cc433e7203440983f0235c2ff4da3e

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Cancer Detection Rates of Systematic and Targeted Prostate Biopsies after Biparametric MRI

Autor: Maudy C. W. Gayet, Anouk A. M. A. van der Aa, Harrie P. Beerlage, Bart Ph Schrier, Maaike Gielens, Roel Heesakkers, Gerrit J. Jager, Peter F. A. Mulders, Hessel Wijkstra

Publikováno v: Prostate Cancer, Vol 2020 (2020)

Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent

Externí odkaz: https://doaj.org/article/78284e166bc54b9da16d3cc24506bfff

Zobrazit plný text záznamu

Plný text ve formátu HTML

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer

Autor: Wieke C. H. Visser, Hans de Jong, Sandra Steyaert, Willem J. G. Melchers, Peter F. A. Mulders, Jack A. Schalken

Publikováno v: Prostate Cancer and Prostatic Diseases, 25, 583-589
Prostate Cancer and Prostatic Diseases, 25, 3, pp. 583-589

Background Molecular biomarker tests are developed as diagnostic tools for prostate cancer (PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary-based biomarker test intended to be used to predict presence of high-gr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8d2ea4901ed564e24a87ce42379b88
https://doi.org/10.1038/s41391-022-00562-1

Zobrazit plný text záznamu

Combination of sunitinib and

Autor: Jeannette C, Oosterwijk-Wakka, Mirjam C A, de Weijert, Gerben M, Franssen, Dimitar R, Kolev, Ton A F J, de Haan, Otto C, Boerman, Peter F A, Mulders, Egbert, Oosterwijk

Publikováno v: Neoplasia (New York, N.Y.). 32

Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2d5d530b97425d5cc2f6c45fc7a53b63
https://pubmed.ncbi.nlm.nih.gov/35878454

Zobrazit plný text záznamu

Abstracts voorjaarsvergadering NVU, 16 en 17 mei 2019, Rotterdam

Autor: Peter F. A. Mulders

Publikováno v: Tijdschrift voor Urologie. 9:2-29

De FUTURE trial is een multicenter RCT naar MRI target biopten (TB’s) bij patienten met negatieve systematische biopten (SB’s) en een verdenking op prostaatkanker. In deze analyse werden adverse events (AE) van drie technieken van TB vergeleken.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec81a0de4557228b33039a2d665f43cc
https://doi.org/10.1007/s13629-019-0255-6

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání